Denosumab.
Rizzoli
René
R
Yasothan
Uma
U
Kirkpatrick
Peter
P
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015519:Bone Density / Q000187:drug effects; D000069448:Denosumab; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D053245:RANK Ligand / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab